PharmAbcine Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
PharmAbcine Inc. is a clinical stage publically trading biotech company developing therapeutic antibodies to treat cancer, ocular, and vascular diseases by targeting angiogenesis or immuno-oncology areas. We are looking for a partnership to co-develop or license out our preclinical and clinical assets. We are also interested in R&D collaboration to evaluate the opportunity to develop combo therapy.

Key molecules:
Olinvacimab/TTAC-0001 (anti-VEGFR2): Anti-VEGFR2 neutralizing fully human IgG1. It has shown safety and efficacy as mono- and as combo treatment with pembrolizumab in clinical studies. It is currently in three clinical trials: Phase 2a in rGBM patients who progressed on bevacizumab. Phase 1b combo trial with pembrolizumab in rGBM. Phase 1b combo trial with pembrolizumab in mTNBC patients. Olinvacimab received ODD to treat rGBM from Korean MFDS and US FDA.
Ticker:
208340
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
Olinvacimab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
7
Speaker
photo
CEO and President
PharmAbcine, Inc.